Trials Sponsors Conditions Drugs Pricing

Conditions

Keywords

car-tcell therapycytopeniathrombocytopeniaCar T-Cell Therapyprolonged cytopeniamultiple myelomalymphomaavatrombopagdoptelet

Outcome Measures

Primary Outcomes (1)

Number of participants with platelets ≥50K
Number of participants with platelets ≥50K for 2 consecutive laboratory checks within 1 week, and one of those measures occurring at day 28. The last platelet transfusion must be \>2 days from the first day of platelets ≥50K.
From enrollment to Day 35

Secondary Outcomes (7)

Number of participants with platelets ≥30K at day 28
From time of enrollment to day 28
Number of participants with platelets ≥30K at day 14
From time of enrollment to day 14
Platelets ≥100K at day 28
From enrollment to day 28
Platelet transfusion independence
From day of first platelet transfusion until first day of platelets ≥10K without transfusion for 24 hours prior
Length of stay
From Day 0 to Day 60
+2 more secondary outcomes

Study Arms (1)

Avatrombopag Arm

EXPERIMENTAL

All participants are anticipated to receive a 39 day supply of oral Avatrombopag.

Drug: Avatrombopag

Interventions

AvatrombopagDrug

Avatrombopag (Doptelet) - immediate-release tablet, 20 mg

Avatrombopag Arm

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study

Sponsors & Collaborators

Sobi, Inc.
Industrycollaborator
University of Virginia
Otherlead

Study Sites (1)

University of Virginia

Charlottesville, Virginia, 22908, United States

Ann BrownCONTACT434-243-5721 amb8e@uvahealth.org

MeSH Terms

Conditions

ThrombocytopeniaCytopeniaMultiple MyelomaLymphoma

Interventions

avatrombopag

Condition Hierarchy (Ancestors)

Blood Platelet DisordersHematologic DiseasesHemic and Lymphatic DiseasesNeoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular Diseases

Study Officials

Krithika Shanmugasundaram, MD
University of Virginia
PRINCIPAL INVESTIGATOR

Central Study Contacts

Sabeena Ahmad

CONTACT

434-327-7492 dxp2tu@uvahealth.org

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: PREVENTION
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Assistant Professor

Study Record Dates

First Submitted

September 14, 2026

First Posted

October 26, 2026

Study Start

November 2026

Estimated

Planned date reported by the registry; this milestone is not confirmed as achieved.

Primary Completion

August 2029

Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (7)

Study Arms (1)

Avatrombopag Arm

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (7)

Study Arms (1)

Avatrombopag Arm

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations